These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 36298577)
1. Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China. Fu Y; Zhao J; Wei X; Han P; Yang L; Ren T; Zhan S; Li L Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298577 [TBL] [Abstract][Full Text] [Related]
2. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States. Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976 [TBL] [Abstract][Full Text] [Related]
3. mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia. Li R; Liu H; Fairley CK; Ong JJ; Guo Y; Lu P; Zou Z; Xie L; Zhuang G; Li Y; Shen M; Zhang L Vaccine; 2023 Apr; 41(15):2439-2446. PubMed ID: 36781332 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts. Zeng T; Lu Y; Zhao Y; Guo Z; Sun S; Teng Z; Tian M; Wang J; Li S; Fan X; Wang W; Cai Y; Liao G; Liang X; He D; Wang K; Zhao S Respir Res; 2023 Oct; 24(1):246. PubMed ID: 37828565 [TBL] [Abstract][Full Text] [Related]
5. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
6. The effectiveness of booster vaccination of inactivated COVID-19 vaccines against susceptibility, infectiousness, and transmission of omicron BA.2 variant: a retrospective cohort study in Shenzhen, China. Liao Y; Su J; Zhao J; Qin Z; Zhang Z; Gao W; Wan J; Liao Y; Zou X; He X Front Immunol; 2024; 15():1359380. PubMed ID: 38881892 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study. He X; Zeng B; Wang Y; Pang Y; Zhang M; Hu T; Liang Y; Kang M; Tang S Front Immunol; 2023; 14():1257360. PubMed ID: 37915583 [TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of the inactivated COVID-19 vaccines against variant of concerns: meta-analysis. Sarwar MU; Waasia FZ; Aloqbi AA; Alandiyjany M; Alqahtani RM; Hafiz LA; Shamlan G; Albreiki M J Infect Public Health; 2024 Feb; 17(2):245-253. PubMed ID: 38141544 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z; EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study. Zhang X; Wang Y; Hu C; Xu P; Ma L; Liu L; Sun J; Liu Y; Yang H; Pan F; Hu J; Cao C; Cheng K; Gao D; Lyu Y; Qin W Hum Vaccin Immunother; 2023 Dec; 19(1):2194189. PubMed ID: 36998173 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies. Fu Y; Zhao J; Wei X; Han P; Yang L; Ren T; Zhan S; Li L Front Public Health; 2022; 10():917732. PubMed ID: 35928479 [TBL] [Abstract][Full Text] [Related]
12. mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines. Zhang B; Huo J; Huang Y; Teo SY; Duan K; Li Y; Toh LK; Lam KP; Xu S Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891221 [TBL] [Abstract][Full Text] [Related]
13. Relative effectiveness of a heterologous booster dose with adenovirus type 5 vectored COVID-19 vaccine versus three doses of inactivated COVID-19 vaccine in adults during a nationwide outbreak of omicron predominance, in China: a retrospective, individually matched cohort-control study. Jia S; Yin Z; Pan H; Wang F; Liu X; Wang Q; Zhang L; Tang J; Yang H; Du J; Wang Z; Jin P; Peng Z; Tang R; Kang G; Wang X; Li S; Wang W; Li J; Shen H; Zhu F Emerg Microbes Infect; 2024 Dec; 13(1):2332660. PubMed ID: 38678636 [TBL] [Abstract][Full Text] [Related]
14. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. Le P; Rothberg MB J Gen Intern Med; 2017 Feb; 32(2):159-167. PubMed ID: 27743284 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021. Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis. Ren J; Huang Z; Tian J; Li Z; Shen S; Yan H; Wang N; Hu J; Ma X; Ma Z; Liu J; Lu Y; Sun X Vaccine; 2024 Aug; 42(21):126162. PubMed ID: 39069462 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the fourth dose of COVID-19 vaccines against severe COVID-19 among adults 40 years or older in Brazil: a population-based cohort study. Lazar Neto F; Hitchings MDT; Amin AB; de França GVA; Lind ML; Scaramuzzini Torres MS; Tsuha DH; de Oliveira RD; Cummings DAT; Dean NE; Andrews JR; Ko AI; Croda J; Ranzani OT Lancet Reg Health Am; 2024 Jun; 34():100755. PubMed ID: 38737773 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of NVX-CoV2373 COVID-19 vaccination for elderly people in Japan. Kato M; Ono T; Deguchi H; Ohmagari N; Igarashi A Vaccine X; 2024 Aug; 19():100514. PubMed ID: 39108420 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. Wang Y; Shi JF; Wang L; Yan Y; Yao H; Dai M; Chen T; Qu C Int J Infect Dis; 2019 Jan; 78():130-139. PubMed ID: 30466898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]